UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~February~~June 710, 2019

DOUGHERTY’S PHARMACY, INC.

(Exact name of registrant as specified in its charter)

Commission File Number: 000-27945

Delaware	75-2900905
(State or other jurisdiction	(IRS Employer
of incorporation)	Identification No.)

5924 ROYAL LANE, SUITE 250

DALLAS, TEXAS 75230

(Address of principal executive offices and Zip Code)

Registrant’s telephone number, including area code: 972-250-0945

N/A

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the~~ Securities ~~Act~~registered ofpursuant ~~1933~~to ~~(17~~Section ~~CFR §230.405~~12(b) ~~or Rule 12b-2~~ of the ~~Securities Exchange~~ Act ~~of 1934 (17 CFR §240. 12b-2).~~: None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company [_]

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [_]

Item 51.0201 ~~Departure~~Entry ofinto ~~Directors~~a orMaterial ~~Certain~~Definitive ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Agreement.

OnSee ~~February 7, 2019, Dougherty’s Pharmacy, Inc. (~~the ~~“Company”)~~disclosures ~~announced~~set ~~that~~forth itunder ~~has~~Item ~~named Stewart Edington (age 51) as the Company’s new President and Chief Executive Officer~~2.01 Inof ~~addition~~this ~~to those duties, Mr. Edington will also assume temporary duties as the Company’s~~Current ~~Interim~~Report ~~Chief~~on ~~Financial~~Form ~~Officer~~8-K. ~~Jim Leslie, who has been acting as Interim CEO and CFO, will remain as the Company’s Chairman of the Board.~~

~~Edington~~Item ~~brings over 30 years of experience in the pharmacy industry leading some of the largest pharmacy chains in the United States~~2.01 HeCompletion ~~joins Dougherty’s from Gelson’s Pharmacy, where he served as Director~~ of ~~Operations~~Acquisition ~~from~~or ~~2016~~Disposition ~~to 2017. Previously, he was Vice President~~ of ~~Pharmacy Operations at Haggen Food & Pharmacy from 2015 to 2016~~Assets. Edington also served in various roles at Albertsons, including Divisional Pharmacy Manager from 2003 to 2011, and Vice President of Pharmacy Operations from 2011 to 2014. While employed with Albertsons, he helped cultivate a strategy that successfully delivered on a number of operational initiatives, consistently exceeding organizational goals and objectives. He was also an integral part of the turnaround team during his tenure at Albertsons, working closely with Cerberus Capital Management, L.P., a private equity firm that owns and operates Albertsons.

InOn ~~addition~~June to15, ~~this appointment~~2019, the Company ~~has~~ ~~also~~closed ~~appointed~~a ~~John~~sale D.of ~~Abouchar~~its assubsidiary Dougherty’s Pharmacy El, Paso, LLC for a ~~consultant~~purchase ~~and~~price ~~advisor~~of to$285,489.36, with $90,000 of the ~~Company’s~~purchase ~~Board~~price ofto ~~Directors~~be paid in three equal subsequent monthly installments.

Item 95.0107 ~~Financial~~Submission ~~Statements~~of ~~and~~Matters ~~Exhibits~~to a Vote of Security Holders

On June 10, 2019, an annual meeting of the stockholders of Dougherty’s Pharmacy, Inc. (dthe “Company”) was held at The ~~following~~Hilton ~~exhibit~~Dallas Park Cities, 5954 Luther Lane, Dallas, Texas 75225 in isthe ~~furnished~~Belclaire ~~herewith~~Room (the “Annual Meeting”), for the stockholders to vote on the following proposals:

~~99.~~Proposal 1 ~~Press~~: The election of two Class B Director to hold ~~Release~~office ~~Dated~~until ~~February~~the 7,2022 ~~2019~~annual meeting of stockholders and until his successor has been duly elected and qualified.

~~SIGNATURES~~Proposal 2: To ratify the selection of Whitley Penn LLP to be the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019.

~~Pursuant~~The toforegoing proposals were the ~~requirements~~only proposals to be acted ofupon at the ~~Securities~~Annual ~~Exchange~~Meeting. ~~Act~~For ofinformation ~~1934~~regarding such proposals, see the ~~registrant~~Company’s ~~has~~definitive ~~duly~~proxy ~~caused~~statement ~~this~~filed with ~~report~~the toU.S. beSecurities ~~signed~~Exchange Commission by the Company on ~~its~~May ~~behalf~~8, by2018, ~~the~~with ~~undersigned hereunto~~respect ~~duly~~to ~~authorized~~the Annual Meeting.

~~Dated:~~At ~~February~~the 7close of business on April 30, 2019, the record date for the Annual Meeting, there were 23,097,914 shares of the Company’s common stock outstanding and entitled to vote at the Annual Meeting (“Common Stock”). As the holders of 20,943,820 shares of Common Stock, having a majority of the votes that could be cast by the holders of all outstanding shares of stock entitled to vote at any meeting of the Company’s shareholders, were represented in person or by proxy at the Annual Meeting, a quorum was present.

~~Dougherty’s~~Each ~~Pharmacy,~~of ~~Inc~~the foregoing proposals was adopted and approved by the shareholders at the Annual Meeting. ~~By:~~The ~~/s/~~number ~~Stewart~~of ~~Edington~~votes ~~Stewart~~cast ~~Edington~~for ~~President~~or against, as well as abstentions and ~~Chief~~broker ~~Executive~~non-votes, ~~Officer~~if applicable, &with ~~Interim~~respect ~~Chief~~to ~~Financial~~each ~~Officer~~of Proposals 1 and 2 presented at the Annual Meeting are set forth below:

Proposal 1: The election of Anthony J. LeVecchio and Will Cureton as Class B Directors to hold office until the 2022 annual meeting of stockholders and until his successor has been duly elected and qualified.

DIRECTOR CANDIDATES	FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
Anthony J. LeVecchio	10,363,853	52,588	0	0
Will Cureton	9,650,020	766,421	0	0

Proposal 2: To ratify the selection of Whitley Penn LLP to be the Company’s independent registered public accounting firm for the fiscal year ending December 31, 20198.

FOR	AGAINST	ABSTAIN	BROKER NON-VOTE
20,780,319	200,341	25,841	0

Item 8.01 Other Events.

At the June 10, 2019, annual meeting of the Company’s directors, Mr. James C. Leslie resigned his position as Chairman of the Board, and the Board appointed Mr. Troy Phillips to serve in that capacity. Mr. Leslie continues to serve as a Class C Director.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: July 12, 2019

	Dougherty’s Pharmacy, Inc.

	By:	/s/ Stewart I. Edington
		Stewart I. Edington Chief Executive Officer and Interim Chief Financial Officer (Duly Authorized Principal Executive Officer and Principal Financial Officer)

Filing Compare · Dougherty's Pharmacy, Inc.